Literature DB >> 29163970

Effect of low-dose aspirin use on pancreatic cancer development and morphological changes on imaging in IPMN: A long-term cohort study.

Yusuke Takasaki1,2, Naoyoshi Nagata1, Koh Imbe1, Yuya Hisada1, Katsunori Sekine1, Tsuyoshi Tajima3, Mikio Yanase1, Kazuma Fujimoto4, Junichi Akiyama1, Naomi Uemura5.   

Abstract

BACKGROUND: Aspirin use may reduce the incidence of pancreatic cancer (PC), but no data are available regarding its chemopreventive effects on intraductal papillary mucinous neoplasm (IPMN). We aimed to determine whether low-dose aspirin (LDA) reduces PC development and morphological changes on imaging in IPMN patients.
METHODS: A cohort of 448 IPMN patients periodically followed up with imaging tests was analyzed. We used one-to-two propensity score matching to adjust for differences between an LDA group (n = 63) and a non-LDA group (n = 385). Outcomes included increasing cyst diameter, increasing main pancreatic duct (MPD) diameter, mural nodule (MN) appearance and PC development.
RESULTS: After matching, 63 LDA and 126 non-LDA patients were selected. During follow-up (median, 5.5 years), no significant differences were found in increasing cyst diameter, MN appearance, or PC development. However, there were significantly fewer cases of increasing MPD diameter in the LDA group (4.8% vs. 12.7%; p = 0.02). After adjustment for age and sex, LDA still decreased the risk of increasing MPD diameter (hazard ratio, 0.17; p = 0.02).
CONCLUSION: Our results do not support a chemopreventive effect of LDA on PC development. However, LDA reduces further MPD dilation in IPMN patients.

Entities:  

Keywords:  ASA; Chemoprevention; low-dose aspirin; morphological change; surrogate maker

Year:  2017        PMID: 29163970      PMCID: PMC5676545          DOI: 10.1177/2050640617693524

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  29 in total

1.  Branch duct intraductal papillary mucinous neoplasms: does cyst size change the tip of the scale? A critical analysis of the revised international consensus guidelines in a large single-institutional series.

Authors:  Klaus Sahora; Mari Mino-Kenudson; William Brugge; Sarah P Thayer; Cristina R Ferrone; Dushyant Sahani; Martha B Pitman; Andrew L Warshaw; Keith D Lillemoe; Carlos F Fernandez-del Castillo
Journal:  Ann Surg       Date:  2013-09       Impact factor: 12.969

2.  Intraductal mucin-hypersecreting neoplasms of the pancreas. A clinicopathologic study of eight patients.

Authors:  F Rickaert; M Cremer; J Devière; L Tavares; J P Lambilliotte; S Schröder; D Wurbs; G Klöppel
Journal:  Gastroenterology       Date:  1991-08       Impact factor: 22.682

3.  Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.

Authors:  R B D'Agostino
Journal:  Stat Med       Date:  1998-10-15       Impact factor: 2.373

4.  Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy.

Authors:  Wilson T Kwong; Robert D Lawson; Gordon Hunt; Syed M Fehmi; James A Proudfoot; Ronghui Xu; Andrew Giap; Raymond S Tang; Ingrid Gonzalez; Mary L Krinsky; Thomas J Savides
Journal:  Dig Dis Sci       Date:  2015-04-30       Impact factor: 3.199

5.  Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms.

Authors:  Mee Joo Kang; Jin-Young Jang; Soo Jin Kim; Kyoung Bun Lee; Ji Kon Ryu; Yong-Tae Kim; Yong Bum Yoon; Sun-Whe Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

6.  Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study.

Authors:  Gabriele Capurso; Stefania Boccia; Roberto Salvia; Marco Del Chiaro; Luca Frulloni; Paolo Giorgio Arcidiacono; Alessandro Zerbi; Raffaele Manta; Carlo Fabbri; Maurizio Ventrucci; Ilaria Tarantino; Matteo Piciucchi; Antonella Carnuccio; Ugo Boggi; Emanuele Leoncini; Guido Costamagna; Gianfranco Delle Fave; Raffaele Pezzilli; Claudio Bassi; Alberto Larghi
Journal:  Am J Gastroenterol       Date:  2013-03-05       Impact factor: 10.864

7.  Suppressive effect of sulindac on branch duct-intraductal papillary mucinous neoplasms.

Authors:  Tsuyoshi Hayashi; Hirotoshi Ishiwatari; Hideyuki Ihara; Yutaka Kawano; Koichi Takada; Koji Miyanishi; Masayoshi Kobune; Rishu Takimoto; Tomoko Sonoda; Tetsuji Takayama; Junji Kato; Yoshiro Niitsu
Journal:  J Gastroenterol       Date:  2009-06-18       Impact factor: 7.527

8.  Prostaglandin H synthase-dependent mutagenic activation of benzidine in a Salmonella typhimurium Ames tester strain possessing elevated N-acetyltransferase levels.

Authors:  P D Josephy; A L Chiu; T E Eling
Journal:  Cancer Res       Date:  1989-02-15       Impact factor: 12.701

9.  Main-duct intraductal papillary mucinous adenoma of the pancreas.

Authors:  Kensuke Takuma; Terumi Kamisawa; Taku Tabata; Masanao Kurata; Goro Honda; Shin-Ichiro Horiguchi
Journal:  World J Surg Oncol       Date:  2011-11-23       Impact factor: 2.754

10.  What Is the Best Way to Identify Malignant Transformation Within Pancreatic IPMN: A Systematic Review and Meta-Analyses.

Authors:  Asma Sultana; Richard Jackson; Gilbert Tim; Emma Bostock; Eftychia E Psarelli; Trevor F Cox; Robert Sutton; Paula Ghaneh; Michael G T Raraty; John P Neoptolemos; Christopher M Halloran
Journal:  Clin Transl Gastroenterol       Date:  2015-12-10       Impact factor: 4.488

View more
  2 in total

1.  Low-Dose Aspirin and Pancreatic Cancer Risk-Reply.

Authors:  Harvey A Risch
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-06-20       Impact factor: 4.254

2.  Cyclooxygenase-2 and Cytosolic Phospholipase A2 Are Overexpressed in Mucinous Pancreatic Cysts.

Authors:  Elsie T Mensah; Thomas Smyrk; Lizhi Zhang; Benjamin Bick; Christina M Wood-Wentz; Navtej Buttar; Suresh T Chari; Ferga C Gleeson; Michael Kendrick; Michael Levy; Randall Pearson; Bret T Petersen; Santhi Vege; Felicity Enders; Paul Limburg; Mark Topazian
Journal:  Clin Transl Gastroenterol       Date:  2019-04       Impact factor: 4.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.